EGFR and non-small cell lung carcinoma: In the single arm phase II BELIEF trial in 109 Caucasian EGFR-mutant NSCLC patients, combined erlotinib and bevacizumab gave median PFS and OS of 13.2 and 28.2 months, respectively.